Clinical Trial Update: Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 study of ACY-1215 alone and in combination with bortezomib and dexamethasone for multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ACY-1215 (ricolinostat)
• DEXAMETHASONE (Dexamethasone)
• Velcade (bortezomib)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED